EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults

Yingying Fang, Xiaoqian Wang, Lu Qi, Yuanxu Tong, Yali Wei, Zhong Li, Chen Liu, Ju Liu, Xiaoqiang Cheng, Xiaoyun Liu, Fang Liu, Yinjuan Li und 5 weitere

Frontiers in Pharmacology · 18.06.2026 · 17

DOI: 10.3389/fphar.2026.1838620 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.06.2026. Verfasst von Yingying Fang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STSA-1002 is a fully human monoclonal antibody targeting C5a, which plays a critical role in the pathogenesis of virus-induced acute respiratory distress syndrome ARDS (v-ARDS). We investigated safety, pharmacokinetics, pharmacodynamics, and anti-drug antibodies of increasing multiple intravenous doses of STSA-1002 in healthy adults. In vitro studies, STSA-1002 was a high-affinity, selective anti-human C5a monoclonal antibody blocking C5a-mediated reactive oxygen species (ROS) production. Building on the published preclinical results, a randomized, double-blind, placebo-controlled, dose-escalation study was done at a Phase I unit in China. A total of 60 adverse events (AEs) were reported. In the STSA-1002 group (n = 20), 47 AEs occurred in 18 participants (90.0%), corresponding to a mean of 2.6 AEs per participant. In the placebo group (n = 6), 13 AEs occurred in all 6 participants (100%), corresponding to a mean of 2.2 AEs per participant. Grade 2 or greater study drug-related adverse events included neutrophil count decreased, white blood cell count decreased, and aminotransferase increased. C max and AUC 0-t increased in an approximately dose-proportional manner. After the first dose, the mean concentration of free C5a in all dose groups was suppressed to below the lower limit of quantification. This suppression was maintained in all health volunteers until D42 (5 mg/kg) and D56 (10 mg/kg and 20 mg/kg) after multiple doses. Besides, STSA-1002 could downregulate the levels of myeloperoxidase (MPO), neutrophil elastase (NE), and proteinase 3 (PR3). Overall, multiple infusions of STSA-1002 up to 20 mg/kg appear to be safe and well tolerated in healthy participants in China. The safety, PK, and PD data support the continued evaluation of STSA-1002 in larger Phase II studies. Clinical Trial Registration: https://clinicaltrials.gov/ , ID NCT05497635.

Schlagwörter

Stichwörter der Autor:innen

ARDSCOVID-19STSA-1002monoclonal antibodyvirus

Autor:innen und Institutionen

  • Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Staidson Biopharmaceuticals (Beijing) Co., Ltd, Beijing, China.

Zitieren

APA

Fang, Y., Wang, X., Qi, L., Tong, Y., Wei, Y., Li, Z., Liu, C., Liu, J., Cheng, X., Liu, X., Liu, F., Li, Y., Li, Y., Liu, L., Sun, M., Wang, Y., & Wang, X. (2026). Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1838620

Vancouver

Fang Y, Wang X, Qi L, Tong Y, Wei Y, Li Z, et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1838620

BibTeX
@article{Fang2026,
  author = {Fang, Yingying and Wang, Xiaoqian and Qi, Lu and Tong, Yuanxu and Wei, Yali and Li, Zhong and Liu, Chen and Liu, Ju and Cheng, Xiaoqiang and Liu, Xiaoyun and Liu, Fang and Li, Yinjuan and Li, Yan and Liu, Long and Sun, Mingli and Wang, Yu and Wang, Xinghe},
  title = {Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1838620}
}
Kostenlos starten →